US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

107.96

+3.102.96%

Pre-market: 107.00-0.9600-0.89%08:31 EDT

Volume:935.78K

Turnover:100.83M

Market Cap:7.15B

PE:-53.34

High:109.52

Open:105.48

Low:103.86

Close:104.86

52wk High:115.52

52wk Low:14.34

Shares:66.21M

Float Shares:56.65M

Volume Ratio:1.11

T/O Rate:1.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0242

EPS(LYR):-1.8483

ROE:-18.23%

ROA:-12.95%

PB:6.43

PE(LYR):-58.41

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)

Oruka Therapeutics CMO Joana Goncalves disposes 7,000 shares for $435,915.36

Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)

Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)

Barclays Remains a Buy on Oruka Therapeutics (ORKA)

Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential

Oruka Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Oruka Therapeutics Q1 Loss Widens

MT Newswires Live

Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, vs. FactSet Est of Loss $0.55

MT Newswires Live

Oruka Therapeutics Q1 FY26 net loss widens 52% to $31.82 million

Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

MT Newswires Live

Assessing Oruka Therapeutics (ORKA) Valuation After Equity Raise Collaboration Deal And Trial Updates

Simply Wall St.

Halozyme beats Q1 revenue estimates, sets $1 billion buyback

H.C. Wainwright Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Halozyme, Oruka sign global license to develop ORKA-001 using Hypercon technology

Halozyme Therapeutics Inc - Oruka to Make Upfront and Milestone Payments; Halozyme Eligible for Mid-Single Digit Royalties

THOMSON REUTERS

Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential

Simply Wall St.

Oruka COO Laura Sandler disposes 5,000 shares worth $323,940

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ORKA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":107.96,"timestamp":1787342400000,"preClose":104.86,"halted":0,"volume":935783,"hourTrading":{"tag":"盘前","latestPrice":107,"preClose":107.96,"latestTime":"08:31 EDT","volume":139,"amount":14927.41989,"timestamp":1787574703816,"change":-0.96,"changeRate":-0.008892,"amplitude":0.058911},"delay":0,"changeRate":0.029563227160022833,"floatShares":56648688,"shares":66209699,"eps":-2.024183,"marketStatus":"Pre-Mkt","change":3.1,"latestTime":"08-24 09:21:48 EDT","open":105.48,"high":109.52,"low":103.8621,"amount":100831082.398368,"amplitude":0.053957,"askPrice":113.51,"askSize":50,"bidPrice":99.63,"bidSize":323,"shortable":3,"etf":0,"ttmEps":-2.024183,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":107.96,"preHourTrading":{"tag":"盘前","latestPrice":107,"preClose":107.96,"latestTime":"08:31 EDT","volume":139,"amount":14927.41989,"timestamp":1787574703816,"change":-0.96,"changeRate":-0.008892,"amplitude":0.058911},"postHourTrading":{"tag":"盘后","latestPrice":106.82,"preClose":107.96,"latestTime":"19:30 EDT","volume":97369,"amount":10511709.74,"timestamp":1787355003609,"change":-1.14,"changeRate":-0.010559,"amplitude":0.010559},"volumeRatio":1.108910813429518,"impliedVol":0.8199,"impliedVolPercentile":0.236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":56648688,"roa":"-12.95%","roe":"-18.23%","lyrEps":-1.84833,"volumeRatio":1.108910813429518,"shares":66209699,"dividePrice":0,"high":109.52,"amplitude":0.053957,"preClose":104.86,"low":103.8621,"week52Low":14.34,"pbRate":"6.43","week52High":115.515,"institutionHeld":0.9307,"latestPrice":107.96,"committee":0.731903,"eps":-2.024183,"divideRate":0,"volume":935783,"delay":0,"ttmEps":-2.024183,"open":105.48,"prevYearClose":30.31,"prevWeekClose":107.96,"prevMonthClose":96.51,"prevQuarterClose":95.17,"fiveDayClose":111.04,"twentyDayClose":92.16,"sixtyDayClose":57.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-10","symbol":"ORKA","fiscalQuarterEnding":"2026/06","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786334400000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2026-05-13","symbol":"ORKA","fiscalQuarterEnding":"2026/03","expectedEps":-0.52,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2026-03-12","symbol":"ORKA","fiscalQuarterEnding":"2025/12","expectedEps":-0.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2025-11-12","symbol":"ORKA","fiscalQuarterEnding":"2025/09","expectedEps":-0.56,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.55},{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":14,"updateTime":1767758400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2026-08-21","current":-53.335099,"percent":0.019231,"low":-56.341471,"twenty":-31.638621,"median":-12.55157,"eighty":-4.687203,"high":-2.779284,"avg":-17.021481,"sd":14.796983,"marketCap":6942749037},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-27","current":-4.136846,"twenty":-4.523383,"median":-4.154632,"eighty":-3.785238,"marketCap":435433131},{"date":"2025-07-03","current":-4.48188,"twenty":-4.48188,"median":-4.154632,"eighty":-3.808193,"marketCap":471750426},{"date":"2025-07-11","current":-5.004766,"twenty":-4.566552,"median":-4.184867,"eighty":-3.812292,"marketCap":526787975},{"date":"2025-07-18","current":-5.463625,"twenty":-4.701827,"median":-4.197316,"eighty":-3.861483,"marketCap":575086233},{"date":"2025-07-25","current":-5.061679,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"marketCap":532778457},{"date":"2025-08-01","current":-4.834028,"twenty":-4.898055,"median":-4.257786,"eighty":-3.894967,"marketCap":508816530},{"date":"2025-08-08","current":-4.862484,"twenty":-4.898591,"median":-4.281656,"eighty":-3.898524,"marketCap":511811771},{"date":"2025-08-15","current":-5.221398,"twenty":-4.905169,"median":-4.336041,"eighty":-3.910674,"marketCap":561761175},{"date":"2025-08-22","current":-5.148299,"twenty":-5.001209,"median":-4.36364,"eighty":-3.910674,"marketCap":553896518},{"date":"2025-08-29","current":-5.315383,"twenty":-5.050833,"median":-4.460538,"eighty":-3.918873,"marketCap":571872876},{"date":"2025-09-05","current":-5.210955,"twenty":-5.062675,"median":-4.474766,"eighty":-3.936742,"marketCap":560637652},{"date":"2025-09-12","current":-5.621705,"twenty":-5.07235,"median":-4.48188,"eighty":-3.943016,"marketCap":604829531},{"date":"2025-09-19","current":-5.771385,"twenty":-5.152476,"median":-4.546056,"eighty":-3.972962,"marketCap":620933352},{"date":"2025-09-26","current":-5.238803,"twenty":-5.191462,"median":-4.609934,"eighty":-3.980356,"marketCap":563633712},{"date":"2025-10-03","current":-6.676428,"twenty":-5.243928,"median":-4.669033,"eighty":-3.986032,"marketCap":718305289},{"date":"2025-10-10","current":-11.49024,"twenty":-5.309118,"median":-4.714571,"eighty":-3.994896,"marketCap":1236215032},{"date":"2025-10-17","current":-11.944453,"twenty":-5.339054,"median":-4.762887,"eighty":-3.996758,"marketCap":1285083024},{"date":"2025-10-24","current":-12.200791,"twenty":-5.382217,"median":-4.835807,"eighty":-4.005866,"marketCap":1312661989},{"date":"2025-10-31","current":-12.641513,"twenty":-5.468786,"median":-4.862484,"eighty":-4.057038,"marketCap":1360078456},{"date":"2025-11-07","current":-12.717965,"twenty":-5.593858,"median":-4.890941,"eighty":-4.0778,"marketCap":1368303762},{"date":"2025-11-14","current":-11.869655,"twenty":-5.811068,"median":-4.898591,"eighty":-4.08882,"marketCap":1277035540},{"date":"2025-11-21","current":-11.960253,"twenty":-6.69801,"median":-4.937534,"eighty":-4.127114,"marketCap":1306565171},{"date":"2025-11-28","current":-13.338408,"twenty":-7.110152,"median":-4.992317,"eighty":-4.136132,"marketCap":1457117883},{"date":"2025-12-05","current":-13.706211,"twenty":-11.478098,"median":-5.012542,"eighty":-4.13656,"marketCap":1497297545},{"date":"2025-12-12","current":-13.387153,"twenty":-11.950773,"median":-5.056256,"eighty":-4.136846,"marketCap":1462442898},{"date":"2025-12-19","current":-12.474292,"twenty":-12.178774,"median":-5.061679,"eighty":-4.147518,"marketCap":1362719880},{"date":"2025-12-26","current":-14.233544,"twenty":-12.273678,"median":-5.068237,"eighty":-4.154632,"marketCap":1554904531},{"date":"2026-01-02","current":-13.431466,"twenty":-12.335062,"median":-5.068793,"eighty":-4.160323,"marketCap":1467283821},{"date":"2026-01-09","current":-11.698803,"twenty":-12.335062,"median":-5.136174,"eighty":-4.183799,"marketCap":1278003724},{"date":"2026-01-16","current":-14.401935,"twenty":-12.358192,"median":-5.155261,"eighty":-4.187731,"marketCap":1573300040},{"date":"2026-01-23","current":-15.744639,"twenty":-12.45713,"median":-5.171947,"eighty":-4.192073,"marketCap":1719980012},{"date":"2026-01-30","current":-15.624992,"twenty":-12.523037,"median":-5.216176,"eighty":-4.197316,"marketCap":1706909520},{"date":"2026-02-06","current":-13.923348,"twenty":-12.576213,"median":-5.238803,"eighty":-4.205819,"marketCap":1521018069},{"date":"2026-02-13","current":-14.463974,"twenty":-12.717965,"median":-5.287536,"eighty":-4.214018,"marketCap":1580077332},{"date":"2026-02-20","current":-14.366484,"twenty":-12.919201,"median":-5.310162,"eighty":-4.214884,"marketCap":1569427301},{"date":"2026-02-27","current":-15.208444,"twenty":-13.338408,"median":-5.315383,"eighty":-4.240712,"marketCap":1661404842},{"date":"2026-03-06","current":-14.698837,"twenty":-13.396016,"median":-5.355415,"eighty":-4.255652,"marketCap":1605734225},{"date":"2026-03-13","current":-14.507853,"twenty":-13.648603,"median":-5.374559,"eighty":-4.260632,"marketCap":1584870685},{"date":"2026-03-20","current":-18.241416,"twenty":-13.893215,"median":-5.41633,"eighty":-4.275953,"marketCap":1923247264},{"date":"2026-03-27","current":-21.361535,"twenty":-14.059834,"median":-5.48943,"eighty":-4.282885,"marketCap":2252210732},{"date":"2026-04-02","current":-23.696925,"twenty":-14.201638,"median":-5.513424,"eighty":-4.296003,"marketCap":2498437907},{"date":"2026-04-10","current":-29.885474,"twenty":-14.284061,"median":-5.632148,"eighty":-4.323305,"marketCap":3150915147},{"date":"2026-04-17","current":-31.516018,"twenty":-14.426751,"median":-5.771385,"eighty":-4.336613,"marketCap":3322828285},{"date":"2026-04-24","current":-32.251183,"twenty":-14.559692,"median":-6.578962,"eighty":-4.336995,"marketCap":3400338954},{"date":"2026-05-01","current":-32.570171,"twenty":-14.666931,"median":-6.714718,"eighty":-4.368969,"marketCap":3433970886},{"date":"2026-05-08","current":-36.374119,"twenty":-14.779487,"median":-7.118506,"eighty":-4.40896,"marketCap":3835032479},{"date":"2026-05-15","current":-33.151059,"twenty":-15.005487,"median":-11.013542,"eighty":-4.444887,"marketCap":3853943253},{"date":"2026-05-22","current":-30.448133,"twenty":-15.220852,"median":-11.594521,"eighty":-4.464806,"marketCap":3539717207},{"date":"2026-05-29","current":-30.079787,"twenty":-15.26162,"median":-11.787176,"eighty":-4.470498,"marketCap":3496895615},{"date":"2026-06-05","current":-32.31061,"twenty":-15.550545,"median":-11.911508,"eighty":-4.477612,"marketCap":3756237650},{"date":"2026-06-12","current":-35.521957,"twenty":-15.752615,"median":-11.97259,"eighty":-4.48188,"marketCap":4129569555},{"date":"2026-06-18","current":-36.772255,"twenty":-18.655866,"median":-12.082116,"eighty":-4.48188,"marketCap":4274921718},{"date":"2026-06-26","current":-44.943291,"twenty":-19.50544,"median":-12.254757,"eighty":-4.492256,"marketCap":5224837309},{"date":"2026-07-02","current":-48.398471,"twenty":-20.901036,"median":-12.28174,"eighty":-4.533759,"marketCap":5626515902},{"date":"2026-07-10","current":-45.794116,"twenty":-23.696925,"median":-12.328056,"eighty":-4.546056,"marketCap":5323749155},{"date":"2026-07-17","current":-43.080813,"twenty":-28.475782,"median":-12.340203,"eighty":-4.566552,"marketCap":5008316867},{"date":"2026-07-24","current":-47.703285,"twenty":-29.138337,"median":-12.358192,"eighty":-4.57792,"marketCap":5545697686},{"date":"2026-07-31","current":-50.769369,"twenty":-29.924337,"median":-12.387424,"eighty":-4.629142,"marketCap":5902142203},{"date":"2026-08-07","current":-51.059895,"twenty":-30.381727,"median":-12.474292,"eighty":-4.653329,"marketCap":5935916980},{"date":"2026-08-14","current":-53.870179,"twenty":-31.249154,"median":-12.51639,"eighty":-4.666461,"marketCap":7158592655},{"date":"2026-08-21","current":-52.245903,"twenty":-31.638621,"median":-12.55157,"eighty":-4.687203,"marketCap":6942749037}],"updateTime":1787565230007},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635511320","title":"Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635511320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635511320?lang=en_us&edition=fundamental","pubTime":"2026-05-16 09:51","pubTimestamp":1778896283,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA), GH Research (GHRS) and Do...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","BK4137","LU0128526141.USD","BK4551","LABU","BK4535","GHRS","BK4613","XLV","BK4139","ORKA","HCSG","GH","LU0029874061.USD","BK4196","BK4167","BK4581","DOCS","BK4007","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635056279","title":"Oruka Therapeutics CMO Joana Goncalves disposes 7,000 shares for $435,915.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2635056279","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635056279?lang=en_us&edition=fundamental","pubTime":"2026-05-16 08:18","pubTimestamp":1778890686,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Chief Medical Officer Joana Goncalves reported option and warrant exercises totaling 7,000 shares on May 15, 2026, at exercise prices of $6.84 and $7.8.Goncalves also sold 7,000 shares on May 15, 2026, at prices of about $61.56, $62.42, and $63.52.Holdings in common stock ended day at 33,377 shares.Derivative holdings following transactions totaled 207,563 employee stock options and 178,992 employee warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260516:nNDL5blBXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka Therapeutics CMO Joana Goncalves disposes 7,000 shares for $435,915.36","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748952","title":"Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748952?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:21","pubTimestamp":1778764882,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assertio-therapeutics-asrt-aytu-bioscience-aytu-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assertio-therapeutics-asrt-aytu-bioscience-aytu-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASRT","BK4137","BK4588","XLV","LABU","BK4139","LU0029874061.USD","LU0128526141.USD","BK4007","ORKA","BK4581","HCSG","BK4585","XBI","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714572","title":"Piper Sandler Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714572?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:39","pubTimestamp":1778758740,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Oruka Therapeutics, with a price target of $180.00. Rahimi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-reaffirms-their-buy-rating-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635905667","title":"Barclays Remains a Buy on Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635905667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635905667?lang=en_us&edition=fundamental","pubTime":"2026-05-14 17:17","pubTimestamp":1778750279,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Buy rating on Oruka Therapeutics today and set a price target of $160.00. According to TipRanks, Darout ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-buy-on-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635751653","title":"Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2635751653","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635751653?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:55","pubTimestamp":1778709319,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating on May 8. Tyler Van Buren has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oruka-initiated-with-buy-on-best-in-class-orka-001-psoriasis-data-strong-cash-position-and-multi-billion-dollar-upside-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oruka-initiated-with-buy-on-best-in-class-orka-001-psoriasis-data-strong-cash-position-and-multi-billion-dollar-upside-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635775548","title":"Oruka Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635775548","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635775548?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:39","pubTimestamp":1778704745,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryOruka Therapeutics Inc ORKA.OQ reported a quarterly adjusted loss of 45 cents per share for the quarter ended Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753145","title":"Oruka Therapeutics Q1 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753145","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753145?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:19","pubTimestamp":1778703542,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) reported Wednesday Q1 loss of $0.48 per diluted share, compared with a loss of $0.40 a year earlier.Analysts polled by FactSet expected loss of $0.56.The company said cash, cash equivalents and marketable securities totaled $496 million as of March 31.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635535637","title":"Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, vs. FactSet Est of Loss $0.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2635535637","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635535637?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:14","pubTimestamp":1778703243,"startTime":"0","endTime":"0","summary":"Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, vs. FactSet Est of Loss $0.55","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635582977","title":"Oruka Therapeutics Q1 FY26 net loss widens 52% to $31.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635582977","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635582977?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702725,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics posted a wider net loss of USD 31.82 million, up 52% from year-ago quarter.Operating loss widened to USD 36.43 million, a 45% deterioration, as total operating expenses climbed 45% to USD 36.43 million.Research and development costs rose 46% to USD 29.15 million, while general and administrative spending increased 41% to USD 7.29 million.Cash, cash equivalents, and marketable securities totaled USD 496 million as of March 31, 2026; April underwritten offering raised gross proceeds of USD 700.4 million.Phase 2a EVERLAST-A Week 16 data showed 63.5% of ORKA-001 patients achieved PASI 100; Phase 2 ORCA-SURGE trial of ORKA-002 in psoriasis began in February 2026 with data expected in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6P12d0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635941758","title":"Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635941758","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635941758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:03","pubTimestamp":1778702580,"startTime":"0","endTime":"0","summary":"ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026. ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027. Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001. MENLO PARK, Calif., May 13, 2026  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis , today reported first quarter 2026 financial results and provided a corporate update.\"This was an important period for our company as we saw interim data for ORKA-001 that hit the upper end of our expectations on all aspects,\" said Lawrence Klein, PhD, Chief Executive Officer of Oruka. \"Based on this data we were able to strengthen our balance sheet and provide runway through completion of late-stage development for that pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4181","PD","03160","BK4539","LU1169590202.USD","BK4007","BK4099","BK4218","BK4023","PK","BK4585","BK4139","BK4555","LU1169589451.USD","BK4604","TM","LENZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245198","title":"Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245198","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245198?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:54","pubTimestamp":1778601257,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensus on continued royalty-driven outperformance and sustained momentum across its Enhanze portfolio, Mo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","LU0289739699.SGD","LU1093756325.SGD","BK4127","LU2362541513.USD","LU1720051108.HKD","GSK.UK","LU0158827781.USD","LU2362540622.SGD","LU1162221912.USD","LU0106261372.USD","LU0390134368.USD","LU2357305700.SGD","LU2456880835.USD","LU0158827948.USD","LU0314104364.USD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4532","LU0053671581.USD","LU1988902786.USD","VRTX","LU2347655156.SGD","LU0058720904.USD","LU1064131342.USD","LU1244550221.USD","LU2462157665.USD","BK4139","HALO","LU1548497426.USD","LU2271345857.HKD","BK4516","LU0795875169.SGD","LU2089283258.USD","LU0912757837.SGD","LU1791710400.SGD","LU0823416689.USD","SG9999001176.USD","BK4567","ORKA","LU2236285917.USD","GSK","LU2028103732.USD","LU1791710582.SGD","LU1989772923.USD","LU1035775433.USD","GSKH","BK4007","LU0109394709.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634688432","title":"Assessing Oruka Therapeutics (ORKA) Valuation After Equity Raise Collaboration Deal And Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2634688432","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634688432?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:19","pubTimestamp":1778548778,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) stock is drawing attention after a recently completed $700 million common stock offering raised dilution concerns and coincided with volatility around its Halozyme Hypercon collaboration and interim clinical trial updates.\nSee our latest analysis for Oruka Therapeutics.\nAt a latest share price of US$65.68, Oruka’s recent common stock offering, Halozyme Hypercon agreement and interim trial readouts have gone hand in hand with sharp swings, including a 99.76% 3 month...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-after-equity-rai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-after-equity-rai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","EQR","BK4215","BK4585","BK4588","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634237685","title":"Halozyme beats Q1 revenue estimates, sets $1 billion buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2634237685","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634237685?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530347,"startTime":"0","endTime":"0","summary":"Halozyme beats Q1 revenue estimates, sets $1 billion buybackOverviewU.S. biopharma firm's Q1 revenue rose 42% yr/yr, beating analyst expectationsAdjusted EPS for Q1 beat analyst expectationsCompany an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL1N41O0YN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943012","title":"H.C. Wainwright Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943012?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:58","pubTimestamp":1778237905,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics today and set a price target of $120.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633136448","title":"BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber","url":"https://stock-news.laohu8.com/highlight/detail?id=2633136448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633136448?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:24","pubTimestamp":1778073888,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, UberWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL6N41J0N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDQ","LUMN","AVTX","ETR","AMCR","CMI","OXY","KHC","ANET","LCID","DIS","QCOM","RXRX","NVDB","MNKD","NVAX","SMCI","COTY","FRPT","NVDA","HUT","NVII","MASS","APO","CVS","ORKA","PODD","SMCL","NYT","DECK","ARM","INTC","UBER","ELAN","AMD","OSCG","CVX","COP","OSCR","GLW","LINT","SMCY","NVDY","INGM","UTHR","XOM","AMDS","BCRX","RSI","COR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633313817","title":"Halozyme, Oruka sign global license to develop ORKA-001 using Hypercon technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2633313817","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633313817?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:06","pubTimestamp":1778069190,"startTime":"0","endTime":"0","summary":"Halozyme entered global exclusive collaboration, license deal with Oruka to use Hypercon technology with ORKA-001 for psoriasis, related inflammatory diseases.Deal grants Oruka exclusive rights for IL-23p19 in psoriatic disease, includes option to add one more target.Terms include upfront payment, future milestones, mid-single-digit royalties on net sales of products using Hypercon.Hypercon microparticle platform aims to cut injection volume for a given dose, support more convenient administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL4mjx0G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633913889","title":"Halozyme Therapeutics Inc - Oruka to Make Upfront and Milestone Payments; Halozyme Eligible for Mid-Single Digit Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2633913889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633913889?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068813,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA15WHQM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","LU0053671581.USD","BK4139","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632983451","title":"Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2632983451","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632983451?lang=en_us&edition=fundamental","pubTime":"2026-05-04 01:24","pubTimestamp":1777829043,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) is back in focus after reporting Phase 2a data showing high complete skin clearance rates for psoriasis patients on ORKA-001, followed almost immediately by a US$700.35 million follow on stock offering.\nSee our latest analysis for Oruka Therapeutics.\nAt a latest share price of US$62.58, Oruka’s 1 day share price return of 8.52% and 7 day return of 9.34% follow a rapid 90 day gain of 82.45% and year to date share price return of 121.37%. The 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-after-phase-2a-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-after-phase-2a-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623235","title":"Oruka COO Laura Sandler disposes 5,000 shares worth $323,940","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623235","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632623235?lang=en_us&edition=fundamental","pubTime":"2026-05-02 06:26","pubTimestamp":1777674379,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Chief Operating Officer Laura Sandler acquired 5,000 common shares via exercise at USD 7.8 on May 1, 2026.Sandler sold 5,000 common shares at prices ranging from USD 62.58 to USD 68.48 on May 1, 2026.Holdings fell to 236,984 common shares following transactions.Employee warrant balance declined to 84,996 shares following exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL77H5tm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oruka COO Laura Sandler disposes 5,000 shares worth $323,940","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":114,"code":"91000000","status":"200"}]}}